Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: A prospective, observational study

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 12, 2012, Pages 1572-1576

  Garcovich, S ^a   Ruggeri, A ^a   D'Agostino, M ^a   Ardito, F ^a   De Simone, C ^a   Delogu, G ^a   Fadda, G ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLOSPORIN A; ETANERCEPT; ETRETIN; GAMMA INTERFERON; INFLIXIMAB; ISONIAZID; METHOTREXATE; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG WITHDRAWAL; FEMALE; HEPATITIS; HUMAN; INTERFERON GAMMA RELEASE ASSAY; INTERMETHOD COMPARISON; LATENT TUBERCULOSIS; MALE; MICROBIOLOGICAL EXAMINATION; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; QUANTIFERON TB GOLD TEST; REVIEW; THORAX RADIOGRAPHY; TUBERCULIN TEST;

ADULT; AGED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; ITALY; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; PSORIASIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84860736109     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04220.x     Document Type: Review

References (19)

1. Schluger NW, Burzynski J,. Recent advances in chest medicine. Chest 2010; 138: 1456-1463.
2. Smith CH, Anstey AV, Barker JNWN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 987-1019.
3. Sánchez-Moya AI, Daudén E,. Diagnosing latent tuberculosis infection in patients with psoriasis under antitumour necrosis factor-α treatment: every new solution breeds new doubts. Br J Dermatol 2011; 164: 208-209.
4. Centers for Disease Control and Prevention. Controlling tuberculosis in the United States: recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR 2005; 54 (No. RR-12). URL http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5412a1.htm (last accessed 26 June 2011).
5. Mori T, Sakatani M, Yamagishi F, et al. Specific detection of tuberculosis infection: an interferon-gamma based assay using new antigens. Am J Resp Crit Care Med 2004; 170: 59-64.
6. Bieber J, Kavanaugh A,. Tuberculosis and opportunistic infections: relevance to biologic agents. Clin Exp Rheumatol 2004; 22: 126-133.
7. Wallis RS,. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 2008; 8: 601-611.
8. Pai M, Zwerling A, Menzies D,. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008; 149: 177-184.
9. Diel R, Goletti D, Ferrara G, et al. Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011; 37: 88-99.
10. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl. 2): 1-70.
11. National Collaborating Centre for Chronic Conditions (UK). Tuberculosis: Clinical diagnosis and management of tuberculosis, and measures for its prevention and control [Internet]. Royal College of Physicians (UK), London, 2006. URL http://egap.evidence.nhs.uk/CG33 (last accessed 13 March 2011).
12. Naseer A, Naqvi S, Kampmann B,. Evidence for boosting Mycobacterium tuberculosis-specific INF-Î responses at 6 weeks following tuberculin skin testing. Eur Resp J 2007; 29: 1282-1283.
13. World Health Organization: tuberculosis country profile-Italy. URL https://extranet.who.int/sree/Reports?op=Replet&name=%2FWHO-HQ- Reports%2FG2%2FPROD%2FEXT%2FTBCountryProfile&ISO2=IT&outtype=html (last accessed 15 April 2011).
14. Laffitte E, Janssens JP, Roux-Lombard P, et al. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-Î release assay vs. tuberculin skin test. Br J Dermatol 2009; 161: 797-800.
15. â)-TB Gold testing in psoriasis patients treated with tumour necrosis factor blockers in Taiwan. Br J Dermatol 2011; 164: 553-559.
16. Tsiouri G, Gaitanis G, Kiorpelidou D, et al. Tuberculin skin test overestimates tuberculosis hypersensitivity in adult patients with psoriasis. Dermatology 2009; 219: 119-125.
17. Bassukas ID, Kosmidou M, Gaitanis G, et al. Patients with psoriasis are more likely to be treated for latent tuberculosis infection prior to biologics than patients with inflammatory bowel disease. Acta Derm Venereol 2011; 91: 444-6 [Epub ahead of print].
18. Ewer K, Millington KA, Deeks JJ, et al. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med 2006; 174: 831-839.
19. van Brummelen SE, Bauwens AM, Schlösser NJ, et al. Kinetics of a tuberculosis-specific gamma interferon release assay in military personnel with a positive tuberculin skin test. Clin Vaccine Immunol 2010; 17: 937-943.